Glyco-modified atrial natriuretic peptide

Patent metadata

Field	Value
Publication number	US-10947289-B2
Application number	US-201514806487-A
Country	US
Kind code	B2
Filing date	Jul 22, 2015
Priority date	Jan 23, 2013
Publication date	Mar 16, 2021
Grant date	Mar 16, 2021

Abstract

The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.

First claim

The invention claimed is:

1. A modified peptide or a pharmaceutically acceptable salt thereof, wherein the modified peptide has a structure of

wherein hANP is hANP(1-28) consisting of the amino acid sequence of SEQ ID NO: 1 and is bonded at the N terminus of the amino acid sequence to the linker structure through an amide bond; and
SG is a sugar substance of following formula

wherein Gxx is GlcNAc and “O/N-L” represents binding to the linker structure through an O-glycosidic bond.

2. The modified peptide or pharmaceutically acceptable salt according to claim 1 ,
wherein the pharmaceutically acceptable salt is a trifluoroacetate salt or an acetate salt.

3. A medicament comprising a modified peptide or a pharmaceutically acceptable salt according to claim 1 .

4. The medicament according to claim 3 , wherein the medicament is an agent for treating or alleviating a cardiovascular disease.

5. The medicament according to claim 4 , wherein the medicament is an agent for management of a medical condition after the onset of acute heart failure.

6. A medicament comprising a modified peptide or a pharmaceutically acceptable salt according to claim 1 .

7. The medicament according to claim 6 , wherein the medicament is an agent for treating or alleviating a cardiovascular disease.

8. The medicament according to claim 7 , wherein the medicament is an agent for management of a medical condition after the onset of acute heart failure.

9. A method for treating or alleviating a cardiovascular disease comprising
administering the modified peptide or a pharmaceutically acceptable salt according to claim 1 to a patient in need thereof.

10. A method for management of a medical condition after the onset of acute heart failure comprising
administering the modified peptide or pharmaceutically acceptable salt according to claim 1 to a patient in need thereof.

11. A method for treating or alleviating a cardiovascular disease comprising
administering the modified peptide or a pharmaceutically acceptable salt according to claim 2 to a patient in need thereof.

12. A method for management of a medical condition after the onset of acute heart failure comprising
administering the modified peptide or pharmaceutically acceptable salt according to claim 2 to a patient in need thereof.

Assignees

• Daiichi Sankyo Co Ltd

Inventors

• Iwamoto Mitsuhiro
• Yamaguchi Takahiro
• Mori Yutaka
• Saito Keiji
• Honda Takeshi
• Nagayama Takahiro

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K47/549

  Sugars, nucleosides, nucleotides or nucleic acids · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61K47/60

  the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title